Epidemiology of polycythemia vera in a Mexican population
- 7 Downloads
Epidemiology of polycythemia vera (PV) is derived from cohort studies in Western populations. PV studies in the Latin population are limited and have described a lower prevalence of JAK2 mutation. A retrospective cohort of 90 Mexican patients from a single center with PV according to the 2016 World Health Organization diagnostic criteria was studied to establish clinical presentation in Mexicans and evaluate risk factors for mortality and vascular events. At diagnosis, the median age was 59 years; half were females, 90.7% harbored the JAK2 V617F mutation, and 7.1% had an exon 12 mutation. Arterial and venous thromboses were observed in 13.3 and 27.8% of patients, respectively. Seventy-one patients received hydroxyurea and one interferon alpha-2a, of which 51.5% achieved a complete response and 25.0% a partial response. The incidence rate for postdiagnosis arterial thrombosis was 2.68 cases per 100 person–years, for venous thrombosis 2.84, for major hemorrhage 2.57, for progression to myelofibrosis 1.14, and for leukemic transformation 0.44. The mortality rate was 3.54 cases per 100 person–years, and median of survival was 150 months. In multivariable analysis, survival was adversely affected by leukocytosis ≥12 × 109/L (p = 0.013); thrombocytosis ≥450 × 109/L was a risk factor for arterial thrombosis (p = 0.023), and anticoagulation at diagnosis for major hemorrhage (p = 0.049). In conclusion, epidemiology of PV in Mexican population is similar to that reported in Western studies, but with more venous thrombosis at diagnosis and a higher incidence of vascular complications postdiagnosis.
KeywordsErythrocytosis Thrombosis Myeloproliferative disease Prognostic factors Latin
The authors thank the Laboratory of Hematology and the Laboratory of Pathology for running JAK2 mutations tests and quantifying allele burden when necessary.
A. Olivas-Martinez conceived and designed the study, performed data analysis, contributed to results interpretation and wrote the paper. E.J. Tuna-Aguilar contributed to design of the study, results interpretation, manuscript preparation, and drafted the manuscript. O. Barrales-Benítez, D. Aguilar-León and H.E Hernández-Juárez performed JAK2 mutation tests and contributed to interpretation of the results. D. Montante-Montes-de-Oca reviewed bone marrow biopsies and contributed to results interpretation.
Conflict of interest
A. Olivas-Martinez, O. Barrales-Benítez, D. Montante-Montes-de-Oca, D. Aguilar-León, H.E. Hernández-Juárez, and E. Tuna-Aguilar declare that they have no competing interests.
- 2.Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Blood Cancer J. 2015;5:e337–e8. https://doi.org/10.1038/bcj.2015.64.CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574–9. https://doi.org/10.1038/leu.2010.148.CrossRefPubMedGoogle Scholar
- 12.Labastida-Mercado N, Galindo-Becerra S, Garcés-Eisele J, et al. The mutation profile of JAK2, MPL, and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2015;8:16–21. https://doi.org/10.1016/j.hemonc.2014.12.002.CrossRefPubMedGoogle Scholar
- 14.Barosi G, Mesa R, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia. 2008;22:437–8. https://doi.org/10.1038/sj.leu.2404914.CrossRefPubMedGoogle Scholar
- 17.Barosi G, Birgegard G, Finazzi G. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:948–63. https://doi.org/10.1111/j.1365-2141.2009.08019.x.CrossRefGoogle Scholar
- 18.Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med. 1985;103(3):329-34. https://doi.org/10.7326/0003-4819-103-3-329.CrossRefPubMedGoogle Scholar
- 20.Thurmes PJ, Steensma DP. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. Eur J Haematol. 2006;77:57–60. https://doi.org/10.1111/j.1600-0609.2006.00667.x.CrossRefPubMedGoogle Scholar